NCT01183390

Anastrozole 1 mg Tablets Under Fed Conditions

A Single-Dose, Comparative Bioavailability Study of Two Formulations of Anastrozole 1 mg Tablets Under Fed Conditions

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: Teva Pharmaceuticals USA · Industry
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The objective of this study is to evaluate the comparative bioavailability between Anastrozole 1 mg Tablets (Teva Pharmaceuticals, USA) and Arimidex® 1 mg Tablets (AstraZeneca Pharmaceuticals LP, USA), after a single-dose in healthy subjects under fed conditions.

Detailed description

Criteria for Evaluation: FDA Bioequivalence Criteria Statistical Methods: FDA Bioequivalence Statistical Methods

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Anastrozole	1 mg Tablets
DRUG	Anastrozole	1 mg Tablets

Timeline

• Start date: 2005-09-01
• Primary completion: 2005-10-01
• Completion: 2005-10-01
• First posted: 2010-08-17
• Last updated: 2010-11-16
• Results posted: 2010-11-16

Locations

1 site across 1 country: Canada